首页 > 最新文献

Cardiology discovery最新文献

英文 中文
Non-obstructive Coronary Artery Disease in Chinese Patients with Angina Diagnosed by Coronary Angiography: A Retrospective Study 中国冠状动脉造影诊断的心绞痛患者非阻塞性冠状动脉疾病的回顾性研究
Pub Date : 2021-11-15 DOI: 10.1097/CD9.0000000000000039
Chengfei Peng, S. Nie, Yingxian Sun, Hui Chen, Zuyi Yuan, Y. Gong, Xiaozeng Wang, Yaling Han
Abstract Objective: This study aimed to estimate the proportion of non-obstructive coronary artery disease (CAD) patients in large percutaneous coronary intervention (PCI) centers in China. Methods: The study was conducted at 6 large PCI centers in China from January 1, 2013 to December 31, 2015. Demographic and clinical data were collected from medical records, prescription records, and laboratory reports of patients with symptoms of angina who underwent coronary angiography (CAG). Results: A total of 1713 patients were consecutively screened, 1600 of whom were included in the study. CAG showed that 300 patients had non-obstructive CAD while 1300 had obstructive CAD. Among the 300 patients with non-obstructive CAD, 203 displayed mild coronary stenosis (20%–49%) and 91 had normal coronary status (ie, <20% stenosis). Of the 1300 patients with obstructive CAD, 61.6% (801/1300) had typical symptoms of angina, compared with 49.3% (148/300) for patients with non-obstructive CAD. In addition, there were more women than men in the non-obstructive CAD group, whereas the reverse was observed among obstructive CAD patients. Conclusion: The prevalence of non-obstructive CAD in the Chinese population with coronary heart disease was estimated to be approximately 20%. Additionally, typical angina symptoms were correlated with obstructive CAD, whereas female gender was identified as a risk factor for non-obstructive CAD.
摘要目的:本研究旨在估计中国大型经皮冠状动脉介入治疗(PCI)中心非阻塞性冠状动脉疾病(CAD)患者的比例。方法:研究于2013年1月1日至2015年12月31日在中国6家大型PCI中心进行。人口统计学和临床资料收集自接受冠状动脉造影(CAG)的有心绞痛症状患者的医疗记录、处方记录和实验室报告。结果:共筛选1713例患者,其中1600例纳入研究。CAG显示非梗阻性CAD 300例,梗阻性CAD 1300例。300例非阻塞性CAD患者中,轻度冠脉狭窄203例(20% ~ 49%),冠脉正常91例(即冠脉狭窄<20%)。在1300例梗阻性CAD患者中,61.6%(801/1300)有典型心绞痛症状,而非梗阻性CAD患者为49.3%(148/300)。此外,在非阻塞性CAD组中,女性多于男性,而在阻塞性CAD组中则相反。结论:非阻塞性冠心病在中国冠心病人群中的患病率估计约为20%。此外,典型心绞痛症状与阻塞性CAD相关,而女性性别被确定为非阻塞性CAD的危险因素。
{"title":"Non-obstructive Coronary Artery Disease in Chinese Patients with Angina Diagnosed by Coronary Angiography: A Retrospective Study","authors":"Chengfei Peng, S. Nie, Yingxian Sun, Hui Chen, Zuyi Yuan, Y. Gong, Xiaozeng Wang, Yaling Han","doi":"10.1097/CD9.0000000000000039","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000039","url":null,"abstract":"Abstract Objective: This study aimed to estimate the proportion of non-obstructive coronary artery disease (CAD) patients in large percutaneous coronary intervention (PCI) centers in China. Methods: The study was conducted at 6 large PCI centers in China from January 1, 2013 to December 31, 2015. Demographic and clinical data were collected from medical records, prescription records, and laboratory reports of patients with symptoms of angina who underwent coronary angiography (CAG). Results: A total of 1713 patients were consecutively screened, 1600 of whom were included in the study. CAG showed that 300 patients had non-obstructive CAD while 1300 had obstructive CAD. Among the 300 patients with non-obstructive CAD, 203 displayed mild coronary stenosis (20%–49%) and 91 had normal coronary status (ie, <20% stenosis). Of the 1300 patients with obstructive CAD, 61.6% (801/1300) had typical symptoms of angina, compared with 49.3% (148/300) for patients with non-obstructive CAD. In addition, there were more women than men in the non-obstructive CAD group, whereas the reverse was observed among obstructive CAD patients. Conclusion: The prevalence of non-obstructive CAD in the Chinese population with coronary heart disease was estimated to be approximately 20%. Additionally, typical angina symptoms were correlated with obstructive CAD, whereas female gender was identified as a risk factor for non-obstructive CAD.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"1 1","pages":"223 - 227"},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43698134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interpretation of Annual Report on Cardiovascular Health and Diseases in China 2019 解读《2019中国心血管健康与疾病年度报告》
Pub Date : 2021-11-15 DOI: 10.1097/cd9.0000000000000040
{"title":"Interpretation of Annual Report on Cardiovascular Health and Diseases in China 2019","authors":"","doi":"10.1097/cd9.0000000000000040","DOIUrl":"https://doi.org/10.1097/cd9.0000000000000040","url":null,"abstract":"","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45152314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Effects of Omega-3 Fatty Acids on Chinese Patients with Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis Omega-3脂肪酸对中国心血管危险因素患者的影响:系统评价和荟萃分析
Pub Date : 2021-09-22 DOI: 10.1097/CD9.0000000000000029
Zhu Mei, Hai-xu Song, X. Tian, Dan Liu
Abstract Objective: Fish oil (FO) contains omega-3 that inhibits inflammation and blood lipid metabolism, giving it a protective cardiovascular effect. Due to dietary habits, a majority of large-scale clinical trials examining FO and cardiovascular health have been conducted in the Caucasian populations. However, the effects of FO on cardiovascular inflammation indicators and blood lipid metabolism in the Chinese population remain unclear. This study aimed to perform a meta-analysis to elucidate the impact of FO on cardiovascular health in the Chinese population. Methods: Web searches were utilized to locate records of clinical trials related to cardiovascular health and consumption of FO capsules or fish containing omega-3 in several databases, including PubMed, Medline, Embase, Cochrane Library, CNKI, and ClinicalTrial.gov, etc. We obtained lipid metabolism and related proinflammatory markers as the study outcome. We used Review Manager 5.4 and Stata 16 for the statistical analysis. If the I2 ≥ 30%, a random effects model was used, and if the I2 < 30%, a fixed effects model was used. Results: Twenty eligible trials were shortlisted from >1000 records. The meta-analysis revealed that supplementation with eicosapentaenoic acid and docosahexaenoic acid reduced systolic blood pressure by 1.88  mmHg (95% CI: −4.97 to −1.20, P = 0.23), diastolic blood pressure by 0.86  mmHg (95% CI: −1.79 to 0.06, P = 0.07), fasting blood glucose by 0.05 mmol/L (95% CI: −0.16 to 0.06, P = 0.40), and low-density lipoprotein-cholesterol by 0.12  mmol/L (95% CI: −0.23 to −0.01, P = 0.04), when compared to placebo. However, these supplements increased high-density lipoprotein-cholesterol by 0.03  mmol/L (95% CI: 0.01 to 0.05, P < 0.001), when compared to placebo. Dose subgroup analyses examining total cholesterol found that the low-dose group (mean difference = −0.44, 95% CI: −0.55 to −0.34, P < 0.001) demonstrated the best results. Further, results from dose subgroup analyses showed that the all-dose group demonstrated a decrease in tumor necrosis factor (TNF-α) levels among the study subjects, when compared to other groups. Conclusions: Consumption of FO containing omega-3 fatty acids in the Chinese population can improve lipid metabolism and reduce levels of proinflammatory markers. Therefore, it is necessary to vigorously promote the benefits of consuming FO to prevent cardiovascular diseases throughout China.
摘要目的:鱼油含有抑制炎症和血脂代谢的ω-3,具有保护心血管的作用。由于饮食习惯,大多数检查FO和心血管健康的大规模临床试验都是在高加索人群中进行的。然而,FO对中国人群心血管炎症指标和血脂代谢的影响尚不清楚。本研究旨在进行荟萃分析,以阐明FO对中国人群心血管健康的影响。方法:利用网络搜索在PubMed、Medline、Embase、Cochrane Library、CNKI和ClinicalTrial.gov等多个数据库中查找与心血管健康和食用含有ω-3的FO胶囊或鱼类有关的临床试验记录。我们获得了脂质代谢和相关促炎标志物作为研究结果。我们使用Review Manager 5.4和Stata 16进行统计分析。如果I2≥30%,则使用随机效应模型;如果I2<30%,则采用固定效应模型。结果:20项符合条件的试验从1000多项记录中入围。荟萃分析显示,补充二十碳五烯酸和二十二碳六烯酸可使收缩压降低1.88  mmHg(95%置信区间:−4.97至−1.20,P = 0.23),舒张压降低0.86  mmHg(95%置信区间:-1.79至0.06,P = 0.07),空腹血糖增加0.05 mmol/L(95%置信区间:−0.16至0.06,P = 0.40)和低密度脂蛋白胆固醇增加0.12  mmol/L(95%置信区间:−0.23至−0.01,P = 0.04)。然而,这些补充剂使高密度脂蛋白胆固醇增加了0.03  mmol/L(95%可信区间:0.01~0.05,P < 0.001)。检查总胆固醇的剂量亚组分析发现,低剂量组(平均差异 = −0.44,95%可信区间:-0.55至-0.34,P<0.001)显示出最佳结果。此外,剂量亚组分析结果显示,与其他组相比,全剂量组受试者的肿瘤坏死因子(TNF-α)水平有所下降。结论:在中国人群中食用含有ω-3脂肪酸的FO可以改善脂质代谢,降低促炎标志物水平。因此,有必要在中国各地大力宣传食用FO预防心血管疾病的益处。
{"title":"Effects of Omega-3 Fatty Acids on Chinese Patients with Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis","authors":"Zhu Mei, Hai-xu Song, X. Tian, Dan Liu","doi":"10.1097/CD9.0000000000000029","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000029","url":null,"abstract":"Abstract Objective: Fish oil (FO) contains omega-3 that inhibits inflammation and blood lipid metabolism, giving it a protective cardiovascular effect. Due to dietary habits, a majority of large-scale clinical trials examining FO and cardiovascular health have been conducted in the Caucasian populations. However, the effects of FO on cardiovascular inflammation indicators and blood lipid metabolism in the Chinese population remain unclear. This study aimed to perform a meta-analysis to elucidate the impact of FO on cardiovascular health in the Chinese population. Methods: Web searches were utilized to locate records of clinical trials related to cardiovascular health and consumption of FO capsules or fish containing omega-3 in several databases, including PubMed, Medline, Embase, Cochrane Library, CNKI, and ClinicalTrial.gov, etc. We obtained lipid metabolism and related proinflammatory markers as the study outcome. We used Review Manager 5.4 and Stata 16 for the statistical analysis. If the I2 ≥ 30%, a random effects model was used, and if the I2 < 30%, a fixed effects model was used. Results: Twenty eligible trials were shortlisted from >1000 records. The meta-analysis revealed that supplementation with eicosapentaenoic acid and docosahexaenoic acid reduced systolic blood pressure by 1.88  mmHg (95% CI: −4.97 to −1.20, P = 0.23), diastolic blood pressure by 0.86  mmHg (95% CI: −1.79 to 0.06, P = 0.07), fasting blood glucose by 0.05 mmol/L (95% CI: −0.16 to 0.06, P = 0.40), and low-density lipoprotein-cholesterol by 0.12  mmol/L (95% CI: −0.23 to −0.01, P = 0.04), when compared to placebo. However, these supplements increased high-density lipoprotein-cholesterol by 0.03  mmol/L (95% CI: 0.01 to 0.05, P < 0.001), when compared to placebo. Dose subgroup analyses examining total cholesterol found that the low-dose group (mean difference = −0.44, 95% CI: −0.55 to −0.34, P < 0.001) demonstrated the best results. Further, results from dose subgroup analyses showed that the all-dose group demonstrated a decrease in tumor necrosis factor (TNF-α) levels among the study subjects, when compared to other groups. Conclusions: Consumption of FO containing omega-3 fatty acids in the Chinese population can improve lipid metabolism and reduce levels of proinflammatory markers. Therefore, it is necessary to vigorously promote the benefits of consuming FO to prevent cardiovascular diseases throughout China.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"2 1","pages":"22 - 29"},"PeriodicalIF":0.0,"publicationDate":"2021-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49368854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Normal-Weight Abdominal Obesity: A Risk Factor for Hypertension and Cardiometabolic Dysregulation 体重正常的腹部肥胖:高血压和心脏代谢失调的危险因素
Pub Date : 2021-09-21 DOI: 10.1097/CD9.0000000000000034
Jin-Yu Sun, Q. Qu, Yue Yuan, Guozhen Sun, X. Kong, Wei Sun
Abstract Objective: This study aimed to examine the associations of waist circumference with hypertension and cardiometabolic dysregulation among normal-weight adults. Methods: This cross-sectional study included 8795 normal-weight participants aged 20 to 79 years from the 2009–2018 US National Health and Nutrition Examination Survey. The demographic characteristics and cardiometabolic risk factors across waist circumference quartiles were summarized. We used adjusted multivariate logistic regression models, subgroup analysis, and restricted cubic spline to analyze the association between waist circumference and the prevalence of hypertension. Thereafter, we used the random forest supervised machine learning method, together with least absolute shrinkage and selection operator regression, to select hypertension-related features and created a predictive model based on regression analysis to identify hypertension in normal-weight individuals. Results: Waist circumference was positively correlated with hypertension in the non-adjusted, minimally adjusted, and fully adjusted models, with odds ratios (95% confidence interval) of 2.28 (2.14–2.44), 1.27 (1.12–1.44), and 1.27 (1.12–1.44), respectively. In the fully adjusted model, participants in the highest waist circumference quartile had a higher risk of hypertension relative to those in the lowest quartile, with an odds ratio (95% confidence interval) of 3.87 (1.59–10.34). Sensitivity analysis demonstrated the robustness of the association. In the testing set, the predictive model exhibited good performance, with an area under the curve of 0.803, sensitivity of 0.72, specificity of 0.76, and negative predictive value of 0.84. Conclusions: Measuring waist circumference may improve the evaluation of the risk of hypertension and help to manage cardiometabolic risk in normal-weight individuals.
摘要目的:本研究旨在探讨正常体重成人腰围与高血压和心脏代谢失调的关系。方法:本横断面研究包括2009-2018年美国国家健康与营养调查中年龄在20至79岁之间的8795名体重正常的参与者。总结了各腰围四分位数的人口统计学特征和心脏代谢危险因素。我们采用调整后的多变量logistic回归模型、亚组分析和限制三次样条分析腰围与高血压患病率之间的关系。随后,我们使用随机森林监督机器学习方法,结合最小绝对收缩和选择算子回归,选择高血压相关特征,并建立基于回归分析的预测模型,用于正常体重个体的高血压识别。结果:在未调整、最小调整和完全调整模型中,腰围与高血压呈正相关,比值比(95%置信区间)分别为2.28(2.14-2.44)、1.27(1.12-1.44)和1.27(1.12-1.44)。在完全调整后的模型中,腰围最高四分位数的参与者患高血压的风险高于腰围最低四分位数的参与者,比值比(95%置信区间)为3.87(1.59-10.34)。敏感性分析显示了这种关联的稳健性。在测试集中,预测模型表现出良好的性能,曲线下面积为0.803,灵敏度为0.72,特异性为0.76,阴性预测值为0.84。结论:测量腰围可以改善高血压风险的评估,并有助于控制正常体重个体的心脏代谢风险。
{"title":"Normal-Weight Abdominal Obesity: A Risk Factor for Hypertension and Cardiometabolic Dysregulation","authors":"Jin-Yu Sun, Q. Qu, Yue Yuan, Guozhen Sun, X. Kong, Wei Sun","doi":"10.1097/CD9.0000000000000034","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000034","url":null,"abstract":"Abstract Objective: This study aimed to examine the associations of waist circumference with hypertension and cardiometabolic dysregulation among normal-weight adults. Methods: This cross-sectional study included 8795 normal-weight participants aged 20 to 79 years from the 2009–2018 US National Health and Nutrition Examination Survey. The demographic characteristics and cardiometabolic risk factors across waist circumference quartiles were summarized. We used adjusted multivariate logistic regression models, subgroup analysis, and restricted cubic spline to analyze the association between waist circumference and the prevalence of hypertension. Thereafter, we used the random forest supervised machine learning method, together with least absolute shrinkage and selection operator regression, to select hypertension-related features and created a predictive model based on regression analysis to identify hypertension in normal-weight individuals. Results: Waist circumference was positively correlated with hypertension in the non-adjusted, minimally adjusted, and fully adjusted models, with odds ratios (95% confidence interval) of 2.28 (2.14–2.44), 1.27 (1.12–1.44), and 1.27 (1.12–1.44), respectively. In the fully adjusted model, participants in the highest waist circumference quartile had a higher risk of hypertension relative to those in the lowest quartile, with an odds ratio (95% confidence interval) of 3.87 (1.59–10.34). Sensitivity analysis demonstrated the robustness of the association. In the testing set, the predictive model exhibited good performance, with an area under the curve of 0.803, sensitivity of 0.72, specificity of 0.76, and negative predictive value of 0.84. Conclusions: Measuring waist circumference may improve the evaluation of the risk of hypertension and help to manage cardiometabolic risk in normal-weight individuals.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"2 1","pages":"13 - 21"},"PeriodicalIF":0.0,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48129694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Liver Fibrosis Scoring Systems as Novel Tools for Predicting Recurrent Cardiovascular Events in Patients with a Prior Cardiovascular Event 肝纤维化评分系统作为预测既往心血管事件患者复发心血管事件的新工具
Pub Date : 2021-09-13 DOI: 10.1097/CD9.0000000000000033
Huihui Liu, Yexuan Cao, Jinglu Jin, Yuan-Lin Guo, Cheng-gang Zhu, N. Wu, Q. Hua, Yan-fang Li, Lifeng Hong, Q. Dong, Jian‐Jun Li
Supplemental Digital Content is available in the text Abstract Objective: Regarding the secondary prevention of cardiovascular disease (CVD), there is great interest in preventing recurrent cardiovascular events (RCVEs). The prognostic importance of liver fibrosis scores (LFSs) has previously been reported in various CVDs. We hypothesized that LFSs might also be useful predictors for RCVEs in patients with prior cardiovascular events (CVEs). Herein, we aimed to evaluate the associations of LFSs with RCVEs in a large, real-world cohort of coronary artery disease (CAD) patients with a prior CVE. Methods: In this multicenter prospective study, 6527 consecutive patients with angiography-diagnosed CAD who had experienced a prior CVE (acute coronary syndrome, stroke, percutaneous coronary intervention, or coronary artery bypass grafting) were enrolled. LFSs were computed according to the published formulas: non-alcoholic fatty liver disease fibrosis score (NFS) includes age, body mass index (BMI), impaired fasting glycemia or diabetes mellitus (DM), aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, platelets, and albumin; fibrosis-4 (FIB-4) includes age, AST, ALT, and platelets; Forns score includes age, gamma-glutamyltransferase (GGT), and platelets; BARD includes BMI, AST/ALT ratio, and DM; GGT/platelet ratio includes GGT and platelets; AST/ALT ratio includes AST and ALT; and AST/platelet ratio index includes AST and platelets. The originally reported cutoffs were used for the categorization of low-, intermediate-, and high-score subgroups. All patients were followed up for the occurrence of RCVEs (comprising cardiovascular death, non-fatal myocardial infarction, and stroke). Cox and Poisson regression analyses were used to assess the relationship of baseline LFSs with the risk of RCVE. Results: During a mean follow-up of (54.67 ± 18.80) months, 532 (8.2%) RCVEs were recorded. Intermediate and high NFS, FIB-4, Forns, and BARD scores were independently associated with an increased risk of RCVE (hazard ratios ranging from 1.42 to 1.75 for intermediate scores and 1.35 to 2.52 for high scores). In the subgroup analyses of sex, age, BMI, DM, and hypertension status, the increased risk of RCVEs with high LFSs (NFS, FIB-4, Forns, and BARD) was maintained across the different subgroups (all P < 0.05). Conclusion: This study showed that LFSs are indeed independently associated with RCVEs, suggesting that LFSs may be used as novel tools for risk stratification in CAD patients with a prior CVE.
摘要目的:关于心血管疾病(CVD)的二级预防,人们对预防复发性心血管事件(RCVEs)非常感兴趣。肝纤维化评分(LFSs)在各种心血管疾病中的预后重要性已有报道。我们假设LFS也可能是既往心血管事件(CVE)患者RCVEs的有用预测因素。在此,我们旨在评估既往有CVE的冠状动脉疾病(CAD)患者中LFS与RCVEs的相关性。方法:在这项多中心前瞻性研究中,纳入了6527名连续的血管造影诊断为CAD的患者,他们之前经历过CVE(急性冠状动脉综合征、中风、经皮冠状动脉介入治疗或冠状动脉搭桥术)。LFS根据已发表的公式计算:非酒精性脂肪肝纤维化评分(NFS)包括年龄、体重指数(BMI)、空腹血糖受损或糖尿病(DM)、天冬氨酸转氨酶(AST)/丙氨酸转氨酶(ALT)比值、血小板和白蛋白;纤维蛋白-4(FIB-4)包括年龄、AST、ALT和血小板;Forns评分包括年龄、γ-谷氨酰转移酶(GGT)和血小板;BARD包括BMI、AST/ALT比率和DM;GGT/血小板比率包括GGT和血小板;AST/ALT比值包括AST和ALT;AST/血小板比值指数包括AST和血小板。最初报告的临界值用于低分、中分和高分亚组的分类。对所有患者的RCVEs发生情况(包括心血管死亡、非致命性心肌梗死和中风)进行随访。Cox和Poisson回归分析用于评估基线LFS与RCVE风险的关系。结果:平均随访(54.67 ± 18.80) 记录了532例(8.2%)RCVEs。中等和高NFS、FIB-4、Forns和BARD评分与RCVE风险增加独立相关(中等评分的风险比为1.42至1.75,高分的风险比则为1.35至2.52)。在对性别、年龄、BMI、DM和高血压状况的亚组分析中,不同亚组的LFS(NFS、FIB-4、Forns和BARD)高的RCVEs风险增加(均P < 0.05)。结论:本研究表明LFS确实与RCVEs独立相关,表明LFS可作为既往有CVE的CAD患者风险分层的新工具。
{"title":"Liver Fibrosis Scoring Systems as Novel Tools for Predicting Recurrent Cardiovascular Events in Patients with a Prior Cardiovascular Event","authors":"Huihui Liu, Yexuan Cao, Jinglu Jin, Yuan-Lin Guo, Cheng-gang Zhu, N. Wu, Q. Hua, Yan-fang Li, Lifeng Hong, Q. Dong, Jian‐Jun Li","doi":"10.1097/CD9.0000000000000033","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000033","url":null,"abstract":"Supplemental Digital Content is available in the text Abstract Objective: Regarding the secondary prevention of cardiovascular disease (CVD), there is great interest in preventing recurrent cardiovascular events (RCVEs). The prognostic importance of liver fibrosis scores (LFSs) has previously been reported in various CVDs. We hypothesized that LFSs might also be useful predictors for RCVEs in patients with prior cardiovascular events (CVEs). Herein, we aimed to evaluate the associations of LFSs with RCVEs in a large, real-world cohort of coronary artery disease (CAD) patients with a prior CVE. Methods: In this multicenter prospective study, 6527 consecutive patients with angiography-diagnosed CAD who had experienced a prior CVE (acute coronary syndrome, stroke, percutaneous coronary intervention, or coronary artery bypass grafting) were enrolled. LFSs were computed according to the published formulas: non-alcoholic fatty liver disease fibrosis score (NFS) includes age, body mass index (BMI), impaired fasting glycemia or diabetes mellitus (DM), aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, platelets, and albumin; fibrosis-4 (FIB-4) includes age, AST, ALT, and platelets; Forns score includes age, gamma-glutamyltransferase (GGT), and platelets; BARD includes BMI, AST/ALT ratio, and DM; GGT/platelet ratio includes GGT and platelets; AST/ALT ratio includes AST and ALT; and AST/platelet ratio index includes AST and platelets. The originally reported cutoffs were used for the categorization of low-, intermediate-, and high-score subgroups. All patients were followed up for the occurrence of RCVEs (comprising cardiovascular death, non-fatal myocardial infarction, and stroke). Cox and Poisson regression analyses were used to assess the relationship of baseline LFSs with the risk of RCVE. Results: During a mean follow-up of (54.67 ± 18.80) months, 532 (8.2%) RCVEs were recorded. Intermediate and high NFS, FIB-4, Forns, and BARD scores were independently associated with an increased risk of RCVE (hazard ratios ranging from 1.42 to 1.75 for intermediate scores and 1.35 to 2.52 for high scores). In the subgroup analyses of sex, age, BMI, DM, and hypertension status, the increased risk of RCVEs with high LFSs (NFS, FIB-4, Forns, and BARD) was maintained across the different subgroups (all P < 0.05). Conclusion: This study showed that LFSs are indeed independently associated with RCVEs, suggesting that LFSs may be used as novel tools for risk stratification in CAD patients with a prior CVE.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"1 1","pages":"214 - 222"},"PeriodicalIF":0.0,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44451704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Vascular Smooth Muscle Cell Development and Cardiovascular Malformations 血管平滑肌细胞发育与心血管畸形
Pub Date : 2021-09-13 DOI: 10.1097/cd9.0000000000000035
Lihua Qi, W. Kong, Yi Fu
{"title":"Vascular Smooth Muscle Cell Development and Cardiovascular Malformations","authors":"Lihua Qi, W. Kong, Yi Fu","doi":"10.1097/cd9.0000000000000035","DOIUrl":"https://doi.org/10.1097/cd9.0000000000000035","url":null,"abstract":"","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44799225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Activation of Silent Information Regulator 6 Signaling Attenuates Myocardial Fibrosis by Reducing TGFβ1-Smad2/3 Signaling in a Type 2 Diabetic Animal Model 在2型糖尿病动物模型中,沉默信息调节因子6信号的激活通过减少TGFβ1-Smad2/3信号减弱心肌纤维化
Pub Date : 2021-09-13 DOI: 10.1097/CD9.0000000000000031
Liming Yu, Jian Wang, Xue Dong, Yue Hu, Linyu Luo, Xiaodong Xue, Yang Wang
Abstract Objective: Long-term diabetes can result in ventricular hypertrophic remodeling, tissue fibrosis, myocardial metabolic defection, and eventually, heart failure. Silent information regulator 6 (SIRT6) exerts beneficial effects against cardiovascular diseases. This study is aimed to investigate whether the direct regulation of myocardial SIRT6 signaling affects cardiac performance in the case of diabetes. Meanwhile, we sought to explore the underlying mechanisms. Methods: Sprague Dawley (SD) rats were used in this experiment. Briefly, type 2 diabetic animal model was generated by streptozotocin administration along with feeding a high-fat diet. The SD rats were randomly assigned to non-diabetic group, diabetic group, diabetic injected with empty adenoviral vectors group and diabetic injected with adenoviral vectors expressing SIRT6 group (n = 10, respectively). The animals were kept for another 4 weeks before sacrifice. Cardiac performance was evaluated by echocardiography. Myocardial fibrosis was determined by Masson's trichrome staining. Myocardial SIRT6 signaling and fibrosis related molecules were measured by western blotting. Results: The diabetic myocardium exhibited markedly enhanced TGFβ1-Smad2/3-induced myocardial fibrosis and reduced SIRT6 and AMP-activated protein kinase (AMPK) signaling. After 4 weeks of SIRT6 adenoviral vector infection, myocardial tissues exhibited markedly enhanced SIRT6 and AMPK signaling. Additionally, myocardial fibrosis and TGFβ1-Smad2/3 signaling were both attenuated in the diabetic injected with adenoviral vectors expressing SIRT6 group. Conclusions: SIRT6-AMPK signaling suppressed the progression of tissue fibrosis in diabetes mellitus rats by inhibiting TGFβ1 and its downstream effector Smad2/3. SIRT6 might serve as an alternative therapeutic target for diabetes-related cardiovascular diseases.
摘要目的:长期糖尿病可导致心室肥厚性重塑、组织纤维化、心肌代谢缺陷,最终导致心力衰竭。沉默信息调节因子6(SIRT6)对心血管疾病具有有益作用。本研究旨在研究糖尿病患者心肌SIRT6信号的直接调节是否会影响心脏功能。与此同时,我们试图探索潜在的机制。方法:采用SD大鼠进行实验。简言之,2型糖尿病动物模型是通过链脲佐菌素的给药和高脂肪饮食产生的。SD大鼠随机分为非糖尿病组、糖尿病组、注射腺病毒载体组和注射SIRT6腺病毒载体的糖尿病组(n = 分别为10)。这些动物又被饲养了4年 牺牲前几周。通过超声心动图评估心脏功能。采用Masson三色染色法测定心肌纤维化。通过蛋白质印迹法测定心肌SIRT6信号传导和纤维化相关分子。结果:糖尿病心肌明显增强TGFβ1-Smad2/3诱导的心肌纤维化,降低SIRT6和AMPK信号传导。4之后 SIRT6腺病毒载体感染数周后,心肌组织表现出SIRT6和AMPK信号显著增强。此外,在注射表达SIRT6的腺病毒载体的糖尿病组中,心肌纤维化和TGFβ1-Smad2/3信号传导均减弱。结论:SIRT6-AMPK信号通过抑制TGFβ1及其下游效应物Smad2/3来抑制糖尿病大鼠组织纤维化的进展。SIRT6可能作为糖尿病相关心血管疾病的替代治疗靶点。
{"title":"Activation of Silent Information Regulator 6 Signaling Attenuates Myocardial Fibrosis by Reducing TGFβ1-Smad2/3 Signaling in a Type 2 Diabetic Animal Model","authors":"Liming Yu, Jian Wang, Xue Dong, Yue Hu, Linyu Luo, Xiaodong Xue, Yang Wang","doi":"10.1097/CD9.0000000000000031","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000031","url":null,"abstract":"Abstract Objective: Long-term diabetes can result in ventricular hypertrophic remodeling, tissue fibrosis, myocardial metabolic defection, and eventually, heart failure. Silent information regulator 6 (SIRT6) exerts beneficial effects against cardiovascular diseases. This study is aimed to investigate whether the direct regulation of myocardial SIRT6 signaling affects cardiac performance in the case of diabetes. Meanwhile, we sought to explore the underlying mechanisms. Methods: Sprague Dawley (SD) rats were used in this experiment. Briefly, type 2 diabetic animal model was generated by streptozotocin administration along with feeding a high-fat diet. The SD rats were randomly assigned to non-diabetic group, diabetic group, diabetic injected with empty adenoviral vectors group and diabetic injected with adenoviral vectors expressing SIRT6 group (n = 10, respectively). The animals were kept for another 4 weeks before sacrifice. Cardiac performance was evaluated by echocardiography. Myocardial fibrosis was determined by Masson's trichrome staining. Myocardial SIRT6 signaling and fibrosis related molecules were measured by western blotting. Results: The diabetic myocardium exhibited markedly enhanced TGFβ1-Smad2/3-induced myocardial fibrosis and reduced SIRT6 and AMP-activated protein kinase (AMPK) signaling. After 4 weeks of SIRT6 adenoviral vector infection, myocardial tissues exhibited markedly enhanced SIRT6 and AMPK signaling. Additionally, myocardial fibrosis and TGFβ1-Smad2/3 signaling were both attenuated in the diabetic injected with adenoviral vectors expressing SIRT6 group. Conclusions: SIRT6-AMPK signaling suppressed the progression of tissue fibrosis in diabetes mellitus rats by inhibiting TGFβ1 and its downstream effector Smad2/3. SIRT6 might serve as an alternative therapeutic target for diabetes-related cardiovascular diseases.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"2 1","pages":"6 - 12"},"PeriodicalIF":0.0,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49361820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Rationale and Study Design for Evaluating the Efficacy and Safety of Intracardiac Echocardiography-Guided Minimal-Fluoroscopy Ablation in Patients with Paroxysmal Atrial Fibrillation: A Non-Inferior, Multi-Center, Prospective Randomized Controlled Trial (PAF-ICE Trial) 评估阵发性心房颤动患者心内超声心动图引导的最小荧光镜消融的有效性和安全性的原理和研究设计:一项非劣效、多中心、前瞻性随机对照试验(PAF-ICE试验)
Pub Date : 2021-09-13 DOI: 10.1097/CD9.0000000000000032
R. Jiang, Xingpeng Liu, Ji-dong Zhang, Yu Chen, Rui Wang, Meng-zuo Wu, Deyong Long, Jia Li, Haixiong Wang, Jie Fan, Weizhu Ju, Weili Ge, X. Liu, Hai Deng, Weijian Wang, Pingzhen Yang, Ding Li, Xiaobo Huang, Xiongtao Liu, Hailong Tao, P. Zei, Roderick Tung, Xunzhang Wang, Chen-yang Jiang
Abstract The feasibility and safety of intracardiac echocardiography (ICE)-guided catheter ablation for atrial fibrillation (AF) using a minimal/zero-fluoroscopy approach have recently been reported. This approach helps to reduce ionizing radiation exposure and orthopedic complications resulting from using lead aprons. The objectives of this planned prospective, multicenter randomized controlled trial (RCT) (paroxysmal AF (PAF)-ICE trial; ChiCTR2000033624) are to evaluate the efficacy and safety of ICE-guided minimal-fluoroscopy ablation in patients with PAF and the impact on occupational hazards among lab staff. Patients will be randomized in a 1:1 ratio to 2 groups: minimal fluoroscopy group (n = 216) and traditional approach group (n = 216). In the minimal fluoroscopy group, an ICE catheter will be used for geometry/anatomic construction, transseptal puncture, catheter tracking, and effusion monitoring. Pulmonary vein isolation (PVI) will be performed using an open-irrigated radiofrequency SmartTouch Surround Flow or SmartTouch catheter (Biosense Webster, Diamond Bar, California, USA), and confirmed by a multipolar Lasso or PentaRay catheter (Biosense Webster). In the traditional approach group, an ICE catheter will not be used. Transseptal puncture will be performed under fluoroscopic guidance, with all geometries constructed by mapping the catheters. The primary efficacy endpoint is freedom from AF recurrence (without antiarrhythmic medications) at 12 months after ablation. Other endpoints include duration of lead apron use, measures of intra-procedural efficiency, and peri-procedural complications. This RCT will evaluate the efficacy and safety of ICE-guided minimal-fluoroscopy ablation in patients with PAF, also evaluate the benefits to lab staff (regarding reducing occupational hazards) related to this “minimal/zero-fluoroscopy” and “leadless” mode.
摘要最近报道了使用最小/零荧光透视法进行心内超声心动图(ICE)引导的心房颤动(AF)导管消融的可行性和安全性。这种方法有助于减少电离辐射暴露和使用铅围裙引起的骨科并发症。这项计划中的前瞻性、多中心随机对照试验(RCT)(阵发性房颤(PAF)-ICE试验;ChiCTR200033624)旨在评估ICE引导的最小荧光透视消融术对PAF患者的疗效和安全性,以及对实验室工作人员职业危害的影响。患者将按1:1的比例随机分为两组:最小荧光检查组(n = 216)和传统方法组(n = 216)。在最小荧光镜检查组中,ICE导管将用于几何结构/解剖结构、经中隔穿刺、导管追踪和积液监测。肺静脉隔离(PVI)将使用开放式灌注射频SmartTouch环绕流或SmartTouch导管(Biosense Webster,Diamond Bar,California,USA)进行,并通过多极Lasso或PentaRay导管(Biosense Webster)进行确认。在传统入路组中,不会使用ICE导管。房间隔穿刺将在荧光镜引导下进行,所有几何形状均通过绘制导管图构建。主要疗效终点是12岁时无房颤复发(无抗心律失常药物) 消融后数月。其他终点包括使用铅围裙的持续时间、术中效率的测量以及围手术期并发症。该随机对照试验将评估ICE引导的最小荧光透视消融术对PAF患者的疗效和安全性,并评估与这种“最小/零荧光透视”和“无引线”模式相关的对实验室工作人员的益处(关于减少职业危害)。
{"title":"Rationale and Study Design for Evaluating the Efficacy and Safety of Intracardiac Echocardiography-Guided Minimal-Fluoroscopy Ablation in Patients with Paroxysmal Atrial Fibrillation: A Non-Inferior, Multi-Center, Prospective Randomized Controlled Trial (PAF-ICE Trial)","authors":"R. Jiang, Xingpeng Liu, Ji-dong Zhang, Yu Chen, Rui Wang, Meng-zuo Wu, Deyong Long, Jia Li, Haixiong Wang, Jie Fan, Weizhu Ju, Weili Ge, X. Liu, Hai Deng, Weijian Wang, Pingzhen Yang, Ding Li, Xiaobo Huang, Xiongtao Liu, Hailong Tao, P. Zei, Roderick Tung, Xunzhang Wang, Chen-yang Jiang","doi":"10.1097/CD9.0000000000000032","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000032","url":null,"abstract":"Abstract The feasibility and safety of intracardiac echocardiography (ICE)-guided catheter ablation for atrial fibrillation (AF) using a minimal/zero-fluoroscopy approach have recently been reported. This approach helps to reduce ionizing radiation exposure and orthopedic complications resulting from using lead aprons. The objectives of this planned prospective, multicenter randomized controlled trial (RCT) (paroxysmal AF (PAF)-ICE trial; ChiCTR2000033624) are to evaluate the efficacy and safety of ICE-guided minimal-fluoroscopy ablation in patients with PAF and the impact on occupational hazards among lab staff. Patients will be randomized in a 1:1 ratio to 2 groups: minimal fluoroscopy group (n = 216) and traditional approach group (n = 216). In the minimal fluoroscopy group, an ICE catheter will be used for geometry/anatomic construction, transseptal puncture, catheter tracking, and effusion monitoring. Pulmonary vein isolation (PVI) will be performed using an open-irrigated radiofrequency SmartTouch Surround Flow or SmartTouch catheter (Biosense Webster, Diamond Bar, California, USA), and confirmed by a multipolar Lasso or PentaRay catheter (Biosense Webster). In the traditional approach group, an ICE catheter will not be used. Transseptal puncture will be performed under fluoroscopic guidance, with all geometries constructed by mapping the catheters. The primary efficacy endpoint is freedom from AF recurrence (without antiarrhythmic medications) at 12 months after ablation. Other endpoints include duration of lead apron use, measures of intra-procedural efficiency, and peri-procedural complications. This RCT will evaluate the efficacy and safety of ICE-guided minimal-fluoroscopy ablation in patients with PAF, also evaluate the benefits to lab staff (regarding reducing occupational hazards) related to this “minimal/zero-fluoroscopy” and “leadless” mode.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"1 1","pages":"228 - 232"},"PeriodicalIF":0.0,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49423983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Hemorrhagic Risk Score in Elderly Patients with Coronary Artery Disease and Gastrointestinal Malignant Tumor Comorbidity: A 10-year Clinical Inpatient Data Analysis from 2 Medical Centers 老年冠状动脉疾病和胃肠道恶性肿瘤合并症患者的新型出血风险评分:来自2个医疗中心的10年临床住院患者数据分析
Pub Date : 2021-08-26 DOI: 10.1097/CD9.0000000000000030
N. Bao, Wan-Rong Wang, Huitao Wu, Yabin Wang, Hebin Che, Wenwen Meng, Jiaxin Miao, D. Han, Fan Yin
Abstract Objective: Older patients with comorbidity, such as coronary heart disease (CHD) and malignant gastrointestinal tumors, are at a high risk of bleeding events. However, risk prediction models based on risk factor assessment remain unclear. This study aimed to establish an individualized bleeding risk assessment system based on the analysis of 10-year inpatient clinical big data. Methods: Total clinical data of 56,819 patients with CHD and 25,988 patients with malignant digestive tract tumors (admitted from January 2008 to December 2017) were retrospectively collected at the First and Second Medical Centers of Chinese People's Liberation Army General Hospital. Among them, 1307 patients with CHD and malignant digestive tract tumors were screened as the derivation cohort. The dependent variable was the occurrence of major clinical bleeding events. Baseline statistics and hypothesis tests of differences were performed for independent variables according to the occurrence of bleeding. Decision Tree, eXtreme Gradient Boosting (XGBoost), logistic regression, and random forest models were used for comparison. The accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC) were applied as the criteria for evaluating and verifying model performance. To evaluate this developed model, another cohort comprising 454 patients (admitted from January 2018 to December 2019) was prospectively enrolled as the validation cohort based on the same inclusion and exclusion criteria. Results: Among the 64 variables with <50% missing values, the recursive feature elimination method with a random forest model was used to screen the selected variables. The highest accuracy was obtained following the selection of 10 scalars, and the final model was constructed accordingly. XGBoost demonstrated the best performance comprehensively. The AUC-ROC of this model was 0.981, with an accuracy, sensitivity, and specificity of 0.939, 0.950, and 0.927, respectively. In the validation cohort, the AUC-ROC, accuracy, sensitivity, and specificity of the XGBoost model were 0.702, 0.718, 0.636, and 0.725, respectively. The rate of major bleeding events has a positive correlation with the bleeding risk score quintiles. To allow for convenient clinical application, a smartphone application was developed for easy access and calculation (http://fir.master-wx.com/sghr). Conclusion: We successfully established a risk model and score for predicting bleeding events in older patients with comorbidity, such as CHD and gastrointestinal cancer.
摘要目的:患有冠心病(CHD)和胃肠道恶性肿瘤等合并症的老年患者出血事件的风险较高。然而,基于风险因素评估的风险预测模型仍不明确。本研究旨在建立一个基于10年住院临床大数据分析的个体化出血风险评估系统。方法:回顾性收集2008年1月至2017年12月在中国人民解放军总医院第一、第二医学中心收治的56819例冠心病患者和25988例消化道恶性肿瘤患者的临床资料。其中,1307例CHD和消化道恶性肿瘤患者被筛选为衍生队列。因变量是主要临床出血事件的发生率。根据出血发生情况对自变量进行基线统计和差异假设检验。使用决策树、极限梯度提升(XGBoost)、逻辑回归和随机森林模型进行比较。准确性、灵敏度、特异性和受试者工作特征曲线下面积(AUC-ROC)被用作评估和验证模型性能的标准。为了评估这一开发的模型,根据相同的纳入和排除标准,前瞻性地将另一个包括454名患者(2018年1月至2019年12月入院)的队列纳入验证队列。结果:在64个缺失值<50%的变量中,采用随机森林模型的递归特征消除方法对所选变量进行筛选。在选择10个标量后获得了最高的精度,并相应地构建了最终模型。XGBoost全面展示了最佳性能。该模型的AUC-ROC为0.981,准确度、敏感性和特异性分别为0.939、0.950和0.927。在验证队列中,XGBoost模型的AUC-ROC、准确性、敏感性和特异性分别为0.702、0.718、0.636和0.725。主要出血事件的发生率与出血风险评分五分位数呈正相关。为了方便临床应用,开发了一款智能手机应用程序,便于访问和计算(http://fir.master-wx.com/sghr)。结论:我们成功地建立了预测老年合并症(如冠心病和胃肠道癌症)患者出血事件的风险模型和评分。
{"title":"Novel Hemorrhagic Risk Score in Elderly Patients with Coronary Artery Disease and Gastrointestinal Malignant Tumor Comorbidity: A 10-year Clinical Inpatient Data Analysis from 2 Medical Centers","authors":"N. Bao, Wan-Rong Wang, Huitao Wu, Yabin Wang, Hebin Che, Wenwen Meng, Jiaxin Miao, D. Han, Fan Yin","doi":"10.1097/CD9.0000000000000030","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000030","url":null,"abstract":"Abstract Objective: Older patients with comorbidity, such as coronary heart disease (CHD) and malignant gastrointestinal tumors, are at a high risk of bleeding events. However, risk prediction models based on risk factor assessment remain unclear. This study aimed to establish an individualized bleeding risk assessment system based on the analysis of 10-year inpatient clinical big data. Methods: Total clinical data of 56,819 patients with CHD and 25,988 patients with malignant digestive tract tumors (admitted from January 2008 to December 2017) were retrospectively collected at the First and Second Medical Centers of Chinese People's Liberation Army General Hospital. Among them, 1307 patients with CHD and malignant digestive tract tumors were screened as the derivation cohort. The dependent variable was the occurrence of major clinical bleeding events. Baseline statistics and hypothesis tests of differences were performed for independent variables according to the occurrence of bleeding. Decision Tree, eXtreme Gradient Boosting (XGBoost), logistic regression, and random forest models were used for comparison. The accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC) were applied as the criteria for evaluating and verifying model performance. To evaluate this developed model, another cohort comprising 454 patients (admitted from January 2018 to December 2019) was prospectively enrolled as the validation cohort based on the same inclusion and exclusion criteria. Results: Among the 64 variables with <50% missing values, the recursive feature elimination method with a random forest model was used to screen the selected variables. The highest accuracy was obtained following the selection of 10 scalars, and the final model was constructed accordingly. XGBoost demonstrated the best performance comprehensively. The AUC-ROC of this model was 0.981, with an accuracy, sensitivity, and specificity of 0.939, 0.950, and 0.927, respectively. In the validation cohort, the AUC-ROC, accuracy, sensitivity, and specificity of the XGBoost model were 0.702, 0.718, 0.636, and 0.725, respectively. The rate of major bleeding events has a positive correlation with the bleeding risk score quintiles. To allow for convenient clinical application, a smartphone application was developed for easy access and calculation (http://fir.master-wx.com/sghr). Conclusion: We successfully established a risk model and score for predicting bleeding events in older patients with comorbidity, such as CHD and gastrointestinal cancer.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"1 1","pages":"163 - 172"},"PeriodicalIF":0.0,"publicationDate":"2021-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48485310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
When does the Human Heart Transition from Hyperplastic Myocyte Growth to Myocyte Hypertrophy? 人类心脏何时从增生性心肌细胞生长过渡到心肌细胞肥大?
Pub Date : 2021-07-27 DOI: 10.1097/cd9.0000000000000028
A. Gerdes
{"title":"When does the Human Heart Transition from Hyperplastic Myocyte Growth to Myocyte Hypertrophy?","authors":"A. Gerdes","doi":"10.1097/cd9.0000000000000028","DOIUrl":"https://doi.org/10.1097/cd9.0000000000000028","url":null,"abstract":"","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43686431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Cardiology discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1